Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorPAVANELLI, Ana Carolina-
dc.contributor.authorMANGONE, Flavia Rotea-
dc.contributor.authorYOGANATHAN, Piriya-
dc.contributor.authorBESSA, Simone Aparecida-
dc.contributor.authorNONOGAKI, Suely-
dc.contributor.authorOSORIO, Cynthia A. B. de Toledo-
dc.contributor.authorANDRADE, Victor Piana de-
dc.contributor.authorSOARES, Ibere Cauduro-
dc.contributor.authorMELLO, Evandro Sobrosa de-
dc.contributor.authorMULLIGAN, Lois M.-
dc.contributor.authorNAGAI, Maria Aparecida-
dc.identifier.citationBREAST CANCER RESEARCH AND TREATMENT, v.192, n.1, p.43-52, 2022-
dc.description.abstractPurpose Breast cancer (BC) is considered a heterogeneous disease composed of distinct subtypes with diverse clinical outcomes. Luminal subtype tumors have the best prognosis, and patients benefit from endocrine therapy. However, resistance to endocrine therapies in BC is an obstacle to successful treatment, and novel biomarkers are needed to understand and overcome this mechanism. The RET, BCAR1, and BCAR3 genes may be associated with BC progression and endocrine resistance. Methods Aiming to evaluate the expression profile and prognostic value of RET, BCAR1, and BCAR3, we performed immunohistochemistry on tissue microarrays (TMAs) containing a cohort of 361 Luminal subtype BC. Results Low expression levels of these three proteins were predominantly observed. BCAR1 expression was correlated with nuclear grade (p = 0.057), and BCAR3 expression was correlated with lymph node status (p = 0.011) and response to hormonal therapy (p = 0.021). Further, low expression of either BCAR1 or BCAR3 was significantly associated with poor prognosis (p = 0.005; p = 0.042). Pairwise analysis showed that patients with tumors with low BCAR1/low BCAR3 expression had a poorer overall survival (p = 0.013), and the low BCAR3 expression had the worst prognosis with RET high expression stratifying these patients into two different groups. Regarding the response to hormonal therapy, non-responder patients presented lower expression of RET in comparison to the responder group (p = 0.035). Additionally, the low BCAR1 expression patients had poorer outcomes than BCAR1 high (p = 0.015). Conclusion Our findings suggest RET, BCAR1, and BCAR3 as potential candidate markers for endocrine therapy resistance in Luminal BC.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estadode Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2019/05252-4]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [309524/2017-2]-
dc.relation.ispartofBreast Cancer Research and Treatment-
dc.subjectBreast cancereng
dc.subjectEndocrine resistanceeng
dc.subject.othergdp exchange factoreng
dc.subject.otherantiestrogen resistanceeng
dc.subject.otherendocrine resistanceeng
dc.titleComprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypeseng
dc.rights.holderCopyright SPRINGEReng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Piriya:Queens Univ Kingston, Canc Res Inst, Dept Pathol & Mol Med, 18 Stuart St, Kingston, ON K7L 3N6, Canada-, Simone Aparecida:Univ Sao Paulo, Fac Med, Dept Radiol & Oncol, Discipline Oncol, BR-01246903 Sao Paulo, Brazil; Ctr Translat Res Oncol, Canc Inst Sao Paulo, Lab Mol Genet, BR-01246000 Sao Paulo, Brazil-, Suely:AC Camargo Canc Ctr, Dept Pathol Anat, BR-01509020 Sao Paulo, Brazil-, Cynthia A. B. de Toledo:AC Camargo Canc Ctr, Dept Pathol Anat, BR-01509020 Sao Paulo, Brazil-, Victor Piana de:AC Camargo Canc Ctr, Dept Pathol Anat, BR-01509020 Sao Paulo, Brazil-, Lois M.:Queens Univ Kingston, Canc Res Inst, Dept Pathol & Mol Med, 18 Stuart St, Kingston, ON K7L 3N6, Canada-
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUNITED STATESeng
hcfmusp.relation.referenceAlFakeeh A, 2018, CURR ONCOL, V25, pS18, DOI 10.3747/co.25.3752eng
hcfmusp.relation.referenceArpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045eng
hcfmusp.relation.referenceBankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5eng
hcfmusp.relation.referenceBeca F, 2016, ADV EXP MED BIOL, V882, P169, DOI 10.1007/978-3-319-22909-6_7eng
hcfmusp.relation.referenceBoulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100eng
hcfmusp.relation.referenceBraunstein LZ, 2016, SEMIN RADIAT ONCOL, V26, P9, DOI 10.1016/j.semradonc.2015.08.002eng
hcfmusp.relation.referenceBrinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112eng
hcfmusp.relation.referenceBrufsky AM, 2018, ONCOLOGIST, V23, P528, DOI 10.1634/theoncologist.2017-0423eng
hcfmusp.relation.referenceCabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909eng
hcfmusp.relation.referenceCai DP, 2003, CANCER RES, V63, P6802eng
hcfmusp.relation.referenceCai DP, 2003, J IMMUNOL, V170, P969, DOI 10.4049/jimmunol.170.2.969eng
hcfmusp.relation.referenceCiriello G, 2013, BREAST CANCER RES TR, V141, P409, DOI 10.1007/s10549-013-2699-3eng
hcfmusp.relation.referenceClarke R, 2015, MOL CELL ENDOCRINOL, V418, P220, DOI 10.1016/j.mce.2015.09.035eng
hcfmusp.relation.referenceCross AM, 2016, ONCOGENE, V35, P5850, DOI 10.1038/onc.2016.123eng
hcfmusp.relation.referenceDrilon A, 2018, NAT REV CLIN ONCOL, V15, P151, DOI [10.1038/nrclinonc.2017.188, 10.1038/nrclinonc.2017.175]eng
hcfmusp.relation.referenceEsseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343eng
hcfmusp.relation.referenceFelekkis KN, 2005, MOL CANCER RES, V3, P32eng
hcfmusp.relation.referenceGattelli A, 2020, J MAMMARY GLAND BIOL, V25, P13, DOI 10.1007/s10911-020-09445-4eng
hcfmusp.relation.referenceGattelli A, 2013, EMBO MOL MED, V5, P1335, DOI 10.1002/emmm.201302625eng
hcfmusp.relation.referenceGuo JM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0476-9eng
hcfmusp.relation.referenceKoytiger G, 2013, MOL CELL PROTEOMICS, V12, P1204, DOI 10.1074/mcp.M112.025858eng
hcfmusp.relation.referenceMechera R, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5262-0eng
hcfmusp.relation.referenceMorandi A, 2013, CANCER RES, V73, P3783, DOI 10.1158/0008-5472.CAN-12-4265eng
hcfmusp.relation.referenceMorandi A, 2011, TRENDS MOL MED, V17, P149, DOI 10.1016/j.molmed.2010.12.007eng
hcfmusp.relation.referenceMulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680eng
hcfmusp.relation.referenceNagai MA, 2011, BREAST CANCER RES TR, V126, P1, DOI 10.1007/s10549-010-0867-2eng
hcfmusp.relation.referenceNear RI, 2007, J CELL PHYSIOL, V212, P655, DOI 10.1002/jcp.21059eng
hcfmusp.relation.referenceNigro C. L., 2019, CANC DRUG RESISTANCE, DOI [10.20517/cdr.2019.66, DOI 10.20517/CDR.2019.66]eng
hcfmusp.relation.referencePlaza-Menacho I, 2014, CELL SIGNAL, V26, P1743, DOI 10.1016/j.cellsig.2014.03.032eng
hcfmusp.relation.referencePlaza-Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209eng
hcfmusp.relation.referenceSchrecengost RS, 2007, CANCER RES, V67, P6174, DOI 10.1158/0008-5472.CAN-06-3455eng
hcfmusp.relation.referenceSieuwerts AM, 2014, MOL ONCOL, V8, P1679, DOI 10.1016/j.molonc.2014.07.003eng
hcfmusp.relation.referenceSpanheimer PM, 2014, CLIN CANCER RES, V20, P2115, DOI 10.1158/1078-0432.CCR-13-2221eng
hcfmusp.relation.referenceSubbiah V, 2020, J CLIN ONCOL, V38, P1209, DOI 10.1200/JCO.19.02551eng
hcfmusp.relation.referenceTikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1eng
hcfmusp.relation.referenceTornillo G, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0443-5eng
hcfmusp.relation.referenceTornillo G, 2013, STEM CELLS, V31, P1422, DOI 10.1002/stem.1403eng
hcfmusp.relation.referencevan Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799eng
hcfmusp.relation.referencevan Agthoven T, 2012, INT J CANCER, V131, P1998, DOI 10.1002/ijc.27489eng
hcfmusp.relation.referencevan Agthoven T, 2009, J CLIN ONCOL, V27, P542, DOI 10.1200/JCO.2008.17.1462eng
hcfmusp.relation.referencevan der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120eng
hcfmusp.relation.referenceWallez Yann, 2012, Genes Cancer, V3, P382, DOI 10.1177/1947601912460050eng
hcfmusp.relation.referenceWilson AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065678eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/14
LIM/14 - Laboratório de Investigação em Patologia Hepática

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.55 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.